Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Aspen Confirms ‘Material’ Offers For API Unit Remain Under Consideration

Chemicals And Biochem Segments Saw Increased Sales In FY21; Higher Costs Bit

Executive Summary

Aspen Pharmacare is continuing to ponder offloading another part of its operations, with bids under consideration for its significant API business units. The company only recently sold a basket of products in South Africa to Acino.

You may also be interested in...



Aspen Commits To Further Reshaping If Opportunity Arises

South African’s Aspen Pharmacare has published first-half financials results that match a recent trading update, following a major reshaping. The new-look firm says it has “spent a long time building and a long time justifying building.”

Mylan Strikes €642m Deal For Aspen’s Thrombosis Business In Europe

With Mylan continuing to count down the days until its merger with Pfizer’s Upjohn completes, the US firm has struck a deal to acquire Aspen Pharmacare’s thrombosis business in Europe, bolstering what is already a $4bn operation.

Teva Among Beneficiaries As Bystolic Antitrust Case Dismissed

Purchasers and payers for AbbVie’s Bystolic, formerly belonging to Forest Laboratories, have failed in their antitrust suits against a host of generic manufacturers and the originator.

Topics

Related Companies

UsernamePublicRestriction

Register

GB151368

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel